secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001628280-25-009967
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Pharma Q4 revenue +11.6% to $10.4M; full-year net loss $6.4M
-----------------------------------------------------------------------

- Q4 2024 net revenue $10.4M, up 11.6% YoY; full-year revenue $38M.
- Full-year net loss $6.4M; adjusted loss $1.0M (excl. $1.3M product acquisition costs).
- Cash $18M, total assets $76M, liabilities $53M, shareholders' equity $23M at year-end.
- Phase 2 ifetroban DMD study positive top-line; Vibativ approved in China.
- Kristalose $15.3M, Sancuso $9M, Vibativ $7.2M, Caldolor $5M in 2024 revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828025009967/0001628280-25-009967-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828025009967/cpix-20250304.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-009967

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer